U.S. markets close in 3 hours 13 minutes
  • S&P 500

    4,274.64
    -30.56 (-0.71%)
     
  • Dow 30

    33,982.80
    -169.21 (-0.50%)
     
  • Nasdaq

    12,937.11
    -165.44 (-1.26%)
     
  • Russell 2000

    1,983.43
    -37.10 (-1.84%)
     
  • Crude Oil

    87.22
    +0.69 (+0.80%)
     
  • Gold

    1,774.70
    -15.00 (-0.84%)
     
  • Silver

    19.69
    -0.39 (-1.97%)
     
  • EUR/USD

    1.0173
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    2.9080
    +0.0840 (+2.97%)
     
  • GBP/USD

    1.2046
    -0.0048 (-0.40%)
     
  • USD/JPY

    135.3280
    +1.1130 (+0.83%)
     
  • BTC-USD

    23,443.46
    -348.54 (-1.46%)
     
  • CMC Crypto 200

    556.75
    -16.07 (-2.81%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate

Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Aura Biosciencs Inc. were up 11.3% in premarket trading on Thursday after the company said it received a Fast-Track designation from the Food and Drug Administration for its experimental bladder-cancer treatment. Aura is planning to start the Phase 1 clinical trial for this indication in 2023. The company's stock is down 25.9% this year, while the broader S&P 500 has declined 19.9%.